NCT01169792已完成不适用
Association Between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients With Tamoxifen Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 试验地点
- 2
- 主要终点
- The frequency of the genetic polymorphisms of CYP2D6 in breast cancer patients
研究概览
简要总结
The genetic polymorphisms of the cytochrome P450 may influence on the metabolism of tamoxifen.
The investigators want to
- evaluate the frequency or incidence of the genetic polymorphisms of cytochrome P450 subfamilies(CYP2D6, CYP3A4/5 and CYP2C19) in breast cancer patients, and
- analyze the association between the genetic polymorphisms of cytochrome P450 subfamilies and clinical outcomes in breast cancer patients treated by adjuvant tamoxifen therapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age ≥ 18 years
- •Breast cancer patients who underwent surgery
排除标准
- 未提供
研究组 & 干预措施
Breast cancer patients
Breast cancer patients who underwent surgery with or without chemotherapy, endocrine therapy and/or radiation therapy. The patients are categorized according to the genetic polymorphisms or the activity score of the cytochrome P450 metabolism.
干预措施: tamoxifen (Drug)
结局指标
主要结局
The frequency of the genetic polymorphisms of CYP2D6 in breast cancer patients
The frequency of the genetic polymorphisms of CYP3A4/5 in breast cancer patients
The frequency of the genetic polymorphisms of CYP2C19 in breast cancer patients
次要结局
- The association between the genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen therapy
- The association between the genetic polymorphisms of CYP2C19 and outcomes in breast cancer patients with tamoxifen therapy
- The association between the genetic polymorphisms of CYP3A4/5 and outcomes in breast cancer patients with tamoxifen therapy
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast CancerBreast NeoplasmsTamoxifenNCT00830973Medco Health Solutions, Inc.184
已完成
不适用
Tamoxifen Pharmacokinetics and CYP2D6 Polymorphisms in Asian Women With Hormone Receptor Positive Breast CancerBreast CancerNCT00717015National University Hospital, Singapore
已完成
4 期
Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar SurgeryPainOther Surgical ProceduresImpacted Third Molar ToothCytochrome P450 CYP2C9 Enzyme DeficiencyNCT02450487University of Sao Paulo105
已完成
不适用
Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy VolunteersEfavirenz, Metabolism and Pharmacokinetics ChangesNCT01104376Indiana University61
已完成
不适用
Effect of drug metabolizing enzyme gene polymorphism on selective estrogen receptor modulator pharmacokinetics in breast cancer (JBCRG-12)Breast cancerJPRN-UMIN000001665JBCRG(Japan Breast Cancer Research Group)273